Hitachi General Hospital, Hitachi, Japan.
Hitachi Health Care Center, Hitachi, Japan.
Eur J Med Res. 2023 Jan 18;28(1):31. doi: 10.1186/s40001-022-00976-6.
Fib4 index (Fib4) is clinically used as a noninvasive marker of liver fibrosis. In this study, we aimed to preliminarily investigate whether Fib4 can be used to detect individuals who need assessment for alcoholic liver disease (ALD) in the general population by clarifying the detailed association of Fib4 with alcohol consumption and gamma-glutamyl transferase (GGT) among male workers.
We analyzed data sets on the comprehensive medical examinations of male workers as cross-sectional and retrospectively longitudinal studies. We enrolled 10 782 males (mean age: 52.2 ± 10.2 years) in FY2019 and 7845 males (mean follow-up: 12.6 ± 6.7 years) who could be consecutively followed up for 20 years from FY2000 to FY2019. Data were evaluated using logistic regression and COX proportional analysis.
In the cross-sectional setting, the rate of Fib4 ≥ 2.67 in heavy drinkers (≥ 40 g of ethanol/day) was increased dose dependently in those over 65 years old, and that of body mass index ≥ 30 kg/m was increased in those over 60 years old, but not in those with fatty liver. The odds ratio (OR) (95% confidence interval [CI]) for heavy drinking was 4.30 (95% CI = 1.90-9.72), and GGT ≥ 200 IU/L was considerably high (OR = 29.05 [95% CI = 17.03-49.56]). In the longitudinal setting, heavy drinkers and those with GGT ≥ 200 IU/L at 10 years after the baseline showed an increased risk for Fib4 ≥ 2.67 (hazard ratio = 2.17 [95% CI = 1.58-2.98] and 7.65 [95% CI 5.26-11.12], respectively).
The development of Fib4 ≥ 2.67 after 10 years was associated with heavy alcohol drinking and GGT level ≥ 200 IU/L. Therefore, Fib4 combined with GGT could indicate high risk of ALD. However, clinical examinations and course observations are essentially needed.
Fib4 指数(Fib4)临床上被用作肝纤维化的非侵入性标志物。本研究旨在通过阐明 Fib4 与男性工人饮酒和γ-谷氨酰转移酶(GGT)之间的详细关联,初步探讨 Fib4 是否可用于检测一般人群中需要评估酒精性肝病(ALD)的个体。
我们分析了男性工人综合体检数据集,作为横断面和回顾性纵向研究。我们纳入了 2019 财年的 10782 名男性(平均年龄:52.2±10.2 岁)和 2000 财年至 2019 财年可连续随访 20 年的 7845 名男性(平均随访:12.6±6.7 年)。使用逻辑回归和 COX 比例分析评估数据。
在横断面研究中,在 65 岁以上的重度饮酒者(≥40g 乙醇/天)中,Fib4≥2.67 的比例呈剂量依赖性增加,而在 60 岁以上的体重指数≥30kg/m2的人群中,Fib4≥2.67 的比例也呈剂量依赖性增加,但在非脂肪性肝病患者中则没有。重度饮酒的比值比(OR)(95%置信区间[CI])为 4.30(95%CI=1.90-9.72),GGT≥200IU/L 相当高(OR=29.05 [95%CI=17.03-49.56])。在纵向研究中,基线后 10 年时重度饮酒者和 GGT≥200IU/L 的患者 Fib4≥2.67 的风险增加(风险比[HR]=2.17[95%CI=1.58-2.98]和 7.65[95%CI 5.26-11.12])。
Fib4 在 10 年后≥2.67 的发展与重度饮酒和 GGT 水平≥200IU/L 相关。因此,Fib4 联合 GGT 可能提示 ALD 的高风险。然而,临床检查和病程观察是必不可少的。